PF-04136309 + gemcitabine + nab-paclitaxel

This drug is a **three-drug combination therapy** comprising **PF-04136309** (an investigational small molecule CCR2 inhibitor developed by Pfizer), **gemcitabine** (a nucleoside analog antineoplastic agent), and **nab-paclitaxel** (albumin-bound paclitaxel, a microtubule inhibitor). PF-04136309 functions by blocking the CCL2/CCR2 chemokine axis, thereby inhibiting the recruitment of CCR2-positive inflammatory monocytes from the bone marrow to the tumor, which in turn reduces tumor-associated macrophage (TAM) infiltration and immunosuppression in the tumor microenvironment. This mechanism aims to restore anti-tumor immunity in pancreatic cancer. Gemcitabine and nab-paclitaxel are standard chemotherapeutic agents frequently used for pancreatic cancer. The combination is under investigation primarily for metastatic and locally advanced pancreatic ductal adenocarcinoma, with trials focusing on whether CCR2 inhibition adds benefit to standard chemotherapy regimens[1][3][5][6].

Other names

paclitaxel albumin-bound